3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM)
Gregorc, V, Gaafar, R, Favaretto, A, Grossi, F, Jassem, J, Polychronis, A, Bidoli, P, Tiseo, M, O'Brien, M, Shah, R, Taylor, P, Novello, S, Muzio, A, Bearz, A, Badurak, P, Greillier, L, Fontana, F, Colombi, S, Lambiase, A, Bordignon, C
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data
Knetki-Wroblewska, M., Płużański, A., Tabor, S., Winiarczyk, K., Zaborowska-Szmit, M., Zajda, K., Janowicz Zebrowska, A., Piórek, A., Badurak, P., Jaśkiewicz, P., Kowalski, D.M., Krzakowski, M.J.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice
Knetki-Wroblewska, M., Tabor, S., Płtużański, A., Winiarczyk, K., Sobczuk, P., Lewandowska, Z., Piórek, A., Zajda, K., Janowicz-Zebrowska, A., Zaborowska-Szmit, M., Badurak, P., Borucka, M., Kowalski, D.M., Krzakowski, M.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE
Kawalec, P, Badurak, P, Denisso, T, Jastrzebski, D, Marek, M, Pluzanski, A, Szczesna, A, Szkultecka-Debek, M, Russel-Szymczyk, M
Published in Value in health (2010)
Published in Value in health (2010)
Get full text
Journal Article